The delegation from Dana-Farber Cancer Institute was led by Ms. Katya Losk, Senior Director of International Strategic Partnerships. Also attending were Mr. David Read, Vice President for Ambulatory Operations and Medical Oncology, along with other experts from the Institute.

Representing Bach Mai Hospital were Assoc. Prof. Vu Van Giap, Vice Director of the Hospital; Assoc. Prof. Pham Cam Phuong, Director of the Nuclear Medicine and Oncology Center; Ms. Nguyen Thi Huong, Chief of the Hospital Office; Dr. Vu Van Nhan, Deputy Director of the Bach Mai Institute for Training and Research in Medicine and Pharmacy; together with physicians from the Nuclear Medicine and Oncology Center and staff from the Hospital Office.

During the meeting, representatives of Dana-Farber Cancer Institute introduced an overview of the Institute-one of the world’s leading cancer research and treatment centers. Dana-Farber consistently ranks among the top five cancer centers in the United States for both adult and pediatric oncology and serves as a principal teaching affiliate of Harvard Medical School. The Institute is also designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI).

Physicians and scientists at Dana-Farber have made significant contributions to major advances in modern oncology, particularly in the fields of targeted therapy and immunotherapy. The Institute has been home to two recipients of the Nobel Prize in Physiology or Medicine: William G. Kaelin Jr. (2019) and Baruj Benacerraf (1980).

In addition, Dana-Farber scientists have contributed to the development of 35 out of the 75 new cancer drugs approved in recent years by the U.S. Food and Drug Administration (FDA), highlighting the Institute’s pioneering role in oncology research and innovation.

Speaking at the meeting, Ms. Katya Losk expressed her interest in strengthening collaboration with Bach Mai Hospital in the coming years, particularly in the areas of education, academic exchange, capacity building for oncology physicians, as well as the promotion of joint research programs and clinical trials.

Representatives from Dana-Farber also showed interest in expanding cooperation in fields such as precision medicine, translational oncology, multidisciplinary cancer care models, and academic exchange programs between the two institutions.

On behalf of Bach Mai Hospital, Assoc. Prof. Vu Van Giap expressed appreciation for the interest and goodwill demonstrated by Dana-Farber Cancer Institute. He noted that establishing collaboration with one of the world’s leading cancer centers would open up significant opportunities to enhance professional capacity, advance scientific research, and expand the hospital’s international collaboration network.

Assoc. Prof. Vu Van Giap also shared information about the scale of operations at Bach Mai Hospital-one of Vietnam’s largest special-class general hospitals. Each day, the hospital receives between 8,000 and 10,000 outpatient visits and operates more than 4,000 inpatient beds, providing a rich source of clinical data for scientific research, particularly in areas such as precision medicine, artificial intelligence in healthcare, and clinical trials.

Both sides discussed several potential areas of cooperation for the coming period, including training and expert exchange, collaborative scientific research, the development of clinical trials, and specialized partnership programs in oncology. Bach Mai Hospital also expressed its interest in joining Dana-Farber’s research networks while expanding academic exchange and clinical training initiatives between the two institutions.

The meeting took place in an open, constructive, and collaborative atmosphere. Both sides agreed to continue discussions toward the development and signing of a Memorandum of Understanding (MOU), which will lay the foundation for long-term cooperation in training, scientific research, and improving the quality of cancer care.